Psoriasis

Mark A. Bechtel, M.D.
Director of Dermatology
The Ohio State University
College of Medicine

Psoriasis

- Psoriasis is a chronic skin disorder resulting from a polygenic predisposition combined with triggering factors including trauma, infections, and medications.

- The characteristic lesion is a sharply demarcated erythematous plaque with silvery white scales.

- The most common sites involved are the scalp, elbows, knees, and intergluteal fold.

- Psoriasis has a significant negative impact on the quality of life of affected individuals.
Psoriasis - Epidemiology and Genetics

- Psoriasis involves 2% of the world's population.
- In the U.S., the prevalence may be as high as 4.6%.
- It is estimated that 4.5 million Americans suffer from psoriasis.
- Approximately 1.5 million Americans have moderate to severe psoriasis.
- Psoriatic arthritis occurs in 5-30% of patients, depending on diagnostic criteria utilized.

Psoriasis - Immunology

- An immune mediated disorder
- Predominant TH1 cytokine profile
- Memory effector T-cells (CD45RO+) play a major role
- TNF-alpha is important in psoriatic arthritis and cutaneous psoriasis

Triggering Factors

- Koebner phenomenon – injury to the skin, sunburn
- Infections – especially streptococcal infections, HIV, hepatitis C
- Psychogenic stress
- Medications – lithium, interferon, B-blockers, antimalarials, rapid tapers of corticosteroids
Psoriasis - Associated Medical Conditions

- Patients have an increased risk of lymphoma
- Psoriasis may confer an independent risk of myocardial infarction with the greatest risk in young patients with severe psoriasis.
- Increased incidence of obesity
- Increased incidence of depression
- Increased incidence of metabolic syndrome

Psoriatic Arthritis – Clinical Patterns

- Distal interphalangeal joints of hands and feet
- Oligoarthritis – asymmetrical, 4 or fewer joints
- Polyarthritis – symmetrical, similar to RA, > 5 joints
- Arthritis mutilans
- Spondyloarthropathy
Psoriatic Arthritis

- Patients complain of morning stiffness, usually > 45 minutes in duration.
- Enthesitis – inflammation at tendon insertion into bone
- Dactylitis – inflammation and swelling of a whole digit
- Nail involvement in > 80% of patients
- HLA-B-27 positive in > 80%
- Some anemia, leukopenia, thrombocytopenia

Chronic Plaque Psoriasis

- The most common variant of psoriasis
- Symmetric distribution of sharply defined, erythematous, scaling plaques
- The scalp, elbows, knees, presacrum, hands, and feet are sites of predilection
Guttate Psoriasis

- A common presentation in children
- Often preceded by strep pharyngitis or severe upper respiratory infection
- >50% of patients have elevated ASO, anti-DNase B, or streptozyme titers
- Presents as multiple widespread discrete papules and plaques with white scales

Erythrodermic Psoriasis

- Characterized by generalized erythema and scaling
- Onset may be acute or gradual
- Need to rule out atopic dermatitis, T-cell lymphoma, and pityriasis rubra pilaris

Pustular Variants

- Von Zumbusch pattern – generalized pustules, fever, leukocytosis
- Annular pattern
- Pustulosis of palms and soles
- Acrodermatitis continua of Hallopeau
**Nail Psoriasis**

- Incidence varies from 10-80%
- Psoriasis affects the nail matrix, nail bed, hyponychia
- May produce nail pits, oil spot sign, leukonychia, subungual hyperkeratosis
- Nail involvement is common in psoriatic arthritis

**Treatment - Topical Therapies**

- Topical corticosteroids – first line as monotherapy or in combination
- Vitamin D analogues
- Anthralin
- Topical retinoids
- Coal tar derivatives
### Treatment - Phototherapy

- Broadband UVB
- Narrow band UVB (311-313 nm)
- PUVA – photochemotherapy with UVA
- Excimer laser 308 nm

### Methotrexate - Indications

- Chronic plaque psoriasis (> 20% BSA)
- Pustular psoriasis
- Erythrodermic psoriasis
- Psoriatic arthritis

### Systemic Therapies

- Methotrexate
- Cyclosporine
- Systemic retinoids

### Methotrexate - Contraindications

- Creatinine clearance < 60 ml/min
- Trimethoprim-sulfamethoxazole
- Pregnancy and lactation
- Significant liver abnormalities
- Severe anemia, leukopenia, thrombocytopenia
**Cyclosporine - Indications**

- Severe psoriasis
- Conventional therapies ineffective or inappropriate

**Systemic Retinoids - Indications**

- Severe psoriasis which cannot be managed by topical therapies or light therapy
- Erythrodermic or pustular psoriasis

**Cyclosporine - Contraindications**

- Impaired renal function
- Uncontrolled hypertension
- Past or present malignancy
- History of excessive light therapy
- Active infections

**Systemic Retinoids - Contraindications**

- Moderate to severe liver disease
- Severe kidney dysfunction
- Pregnancy and lactation
- Women of childbearing age who cannot guarantee adequate contraception during therapy and up to 3 years following discontinuation of therapy
- Hyperlipidemia
<table>
<thead>
<tr>
<th>Biologic Agents - Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Patients with moderate to severe psoriasis eligible for systemic treatment</td>
</tr>
<tr>
<td>• Psoriatic arthritis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Biologic Agents - Anti TNF Alpha Targeted Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Etanercept – human fusion protein, receptor inhibitor</td>
</tr>
<tr>
<td>• Infliximab – chimeric monoclonal antibody</td>
</tr>
<tr>
<td>• Adalimumab – human monoclonal antibody</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Biologic Agents - Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Active tuberculosis</td>
</tr>
<tr>
<td>• Significant viral, bacterial, or fungal infections</td>
</tr>
<tr>
<td>• Increased risk for developing sepsis</td>
</tr>
<tr>
<td>• Malignancy within the past 5 years</td>
</tr>
<tr>
<td>• With anti-TNF agents – autoimmune disease, blood dyscrasias, hepatitis B, congestive heart failure, demyelination disorders</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Biologic Agents – Inhibit T-cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Alefacept – human fusion protein targets CD2</td>
</tr>
<tr>
<td>• Efalizumab – humanized antibody – targets CD11a</td>
</tr>
</tbody>
</table>